Dr. Arlene O. Siefker-Radtke on Neoadjuvant Chemotherapy Plus Surgery in Bladder Cancer
Siefker-Radtke says her preferred mathod of neoadjuvant chemotherapy is doxorubicin plus ifosfamide with an alternating regimen of etoposide cisplatin.
Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the pairing of neoadjuvant chemotherapy and surgery in patients with bladder cancer. Siefker-Radtke says her preferred mathod of neoadjuvant chemotherapy is doxorubicin plus ifosfamide with an alternating regimen of etoposide cisplatin.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
